Eone Diagnomics Genome Center

At a glance

Eone Diagnomics Genome Center filed 68 disclosures in the last 12 months, including 7 5% holder, 4 insider and 3 issuance. The most recent key filing was on Jul 10: A major holder's stake rose from 0.00% to 9.21%.

Revenue for 2025 was ₩7.9B, down 74.5% on 2024. It made an operating loss of ₩1.6B. Debt was -295% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.8B and operating loss of ₩2B.

The 2025 annual report lists 63 employees with an average tenure of 3.5 years and average pay of ₩43.6M, #1997 of 2,191 listed companies by average pay. Its 7 directors and auditors were paid ₩32.5M each on average. It paid no cash dividend for 2025. 임경숙 and related parties held 16.68% at year end.

Of 5 recent 5%+ holder reports, 3 raised and 2 cut a stake; the largest stake reported was 48.77% on May 8.

From the 2025 annual report

Staff: 63 (27 men, 36 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩2.7B. Directors and auditors: 7, paid ₩227.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

임경숙 holds 9.12%; with 9 related parties the group holds 16.68% of common shares at year end (from 16.72% at the start of the year).

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports